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Abstract OBJECTIVE: To compare the influence of low and normal endogenous estradiol 
concentration on circulating hGH, IGF-I and IGFBP-3 levels as well as on mutual 
correlations of these parameters. PATIENTS: 45 women (age 30.7 ± 9.0 years, BMI 
25.7 ± 8.0) divided into group A – 15 hypoestrogenic women and group B – 30 
normoestrogenic controls. Neither of the women was menopausal nor hyper-
prolactinemic. METHODS: Blood sample was taken at the standard conditions 
prior to the initiation of hormonal supplementation therapy in group A and at 
the day 3–5 of menstrual cycle in group B. Serum hGH, IGF-I, IGFBP-3, insulin, 
testosterone, sex hormone binding globulin (SHBG) dihydroepiandrosterone sul-
phate (DHEAS) and LH as well as prolactin (PRL), FSH and estradiol levels were 
measured by standard RIA kits. RESULTS: Mean IGF-1, LH, FSH, testosterone 
and estradiol and PRL plasma levels were lower in group A compared to group B. 
There were no significant differences in mean SHBG, insulin and DHEAS levels. 
There were also no differences in mean: age, body mass, BMI as well as percent-
age of each BMI range between groups. Regardless the estradiol level the IGF-I/
age link was found in both groups. A IGF-I/IGFBP-3 relation was found in both 
groups. IGF-I/estradiol link was seen only in group A. In group B hGH/SHBG 
link was found, in group A this relation was indirect. A link between hGH and 
testosterone levels was found only in group B. SHBG was related in group B to 
IGFBP-3, testosterone and to DHEAS. Insulin/IGFBP-3 link was seen in group B. 
The stepwise multiple regression revealed DHEAS and LH as predictors of IGF-I 
level in group A, while in group B none of the parameters predicted IGF-I level. 
The results of the same analysis in case of hGH are as follows: in group A hGH 
level was predicted by estradiol and SHBG. In group B none of factors predicted 
hGH levels. CONCLUSION: Estradiol plasma level is correlated to circulating 
IGF-I, albeit the relation seems to be biphasic.
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INTRODUCTION
The somatotropic axis is affected by hormonal milieu 
(Blake et al. 1997). A number of experiments indicate 
that sex steroids exert either stimulatory or inhibi-
tory action on the somatotropic axis (Caufriez 1997). 
Evidence that estradiol is involved in the regulation of 
human Growth Hormone (hGH) – Insulin-like Growth 
Factor-I (IGF-I) – Insulin-like Growth Factor Binding 
Protein-3 (IGFBP-3) system is provided not only by the 
observation that mean hGH level is higher in women 
than men and that the fall in hGH as well as IGF-I levels 
with aging is correlated to estradiol level but also by the 
fact that estradiol has a direct effect on IGF-I synthesis 
and release independent of hGH. Estradiol plays also a 
permissive role in pituitary hGH release (Ho et al. 1996; 
Kirchengast et al. 1996; Wilson 1997). The latter role 
of estradiol is based on its influence on both pituitary 
increase in IGF-I mRNA as well as on regulation of 
pituitary somatostatin concentration (Hennessey et al. 
1994; Michels et al. 1993).
Ovary in turn, is a site of hGH reception and action, 
where it can potentiate steroidogenesis and gametogen-
esis either directly or via endocrine action (Hesse et al. 
1994). Growth hormone acts both by its receptors local-
ized on granulosa cells as well as corpus luteum and 
indirectly by augmentation of hepatic IGF-I produc-
tion (Sharara & Giudice 1997). IGF-I amplifies hGH 
induced estradiol production by granulosa cells, acting 
synergistically as cogonadotropins (Xu et al. 1997; 
Yoshimura et al. 1996). IGF-I is also regarded as auto/
paracrine mediator of estradiol action (Rajkumar et al. 
1996). Ovarian function is even regarded a more con-
tributing factor for circulating IGF-I levels than aging 
(Blake et al. 1997). 
Estradiol exerts different effects on serum IGF-1 
levels depending on its origin, route of administration 
and dose (Blake et al. 1997). Therefore it seems interest-
ing to compare the influence of low and normal endog-
enous estradiol concentration on circulating hGH, 
IGF-I and IGFBP-3 levels as well as on mutual correla-
tions of these parameters.
MATERIAL AND METHODS
Patients
45 women (mean: age 30.7 ± 9.0 years, body mass 
68.9 ± 22.3 kg, BMI 25.7 ± 8.0) were divided into 2 
groups according to their estradiol level. Group A 
embraces 15 hypoestrogenic women (plasma estradiol 
level below 50 μg/l) whereas group B consisted of 30 
normoestrogenic (plasma estradiol level over 50 μg/l) 
controls. Neither of the women was menopausal nor 
hyperprolactinemic. The women in the study were not 
on any form of contraception. The hormonal contra-
ception wash-out period was 6 months. 
Methods
Each women underwent clinical and gynecological 
evaluation. Body mass as well as height was taken to 
calculate body mass index (BMI). Blood to obtain 
plasma was taken at the standard conditions prior to 
the initiation of hormonal supplementation therapy in 
group A and at the day 3–5 of menstrual cycle in group 
B. Plasma was frozen and kept at –70 °C until hormonal 
evaluation. Plasma hGH, IGF-I, IGFBP-3, insulin, 
testosterone, sex hormone binding globulin (SHBG) 
dihydroepiandrosterone sulphate (DHEAS) and LH as 
well as prolactin (PRL), FSH and estradiol levels were 
measured by standard RIA kits. 
Statistical analysis
Descriptive statistics was applied first. Median and inter-
quantile (IQR) were calculated for all variables studied. 
For comparison between groups the Wilcoxon-rank 
test was used. The mutual relations between parameters 
were evaluated by means of Pearson linear correlation 
coefficients and stepwise multiple regression: p-values 
of 0.05 or less were considered as significant.
RESULTS
There were hardly any differences in means of age, body 
mass, BMI as well as percentages of each BMI range 
between groups (Table 1). Mean LH and FSH levels 
were significantly lower in hypoestrogenic group A 
than in controls (group B) (2.9 ± 5.1 vs 10.4 ± 8.4 IU/l; 
p<0.005; 2.7 ±2.3 vs 6.2 ± 1.9 IU/l p<0.001 resp.). Mean 
plasma prolactin as well as estradiol levels were also 
lower in group A (6.1 ± 4.6 vs 15.3 ± 7.0 μg/l; 23.5 ± 15.2 
vs 118.9 ± 68.7  g/l; p<0.001; resp.) (Table 1). 
Mean IGF-1 level was lower in hypoestrogenic 
women (group A) compared to group B (234.9 ± 156.2 
vs 323.6 ± 127.3 μg/l). There were also no statistically 
significant differences either in mean SHBG, insulin, 
IGFBP-3, hGH or DHEAS levels (Table 2). Mean tes-
tosterone level was lower in group A compared to group 
B (0.42 ± 0.26 vs 0.56 ± 0.18 μg/l; p<0.05) (Table 2).
Regardless the estradiol level the IGF-I/age cor-
relation was found in both groups (rA=–0.57; p<0.02; 
rB=–0.53; p<0.005) (Figure 1). Age/DHEAS relation 
was observed also in both groups (rA=–0.74; p<0.002; 
rB=–0.38; p<0.05). Age dependent increase of the 
body mass and BMI could be observed only in group 
A (hypoestrogenic women) (rA=0.6; p<0.02; rB=0.13; 
NS; rA=0.60; p<0.02; rB=0.21; NS; resp.). Also in group 
A an indirect correlation between age and plasma 
SHBG (r=–0.54;p<0.05) could be observed which was 
not found in group B (r=–0.05; NS), whereas in nor-
moestogenic controls (group B), there was an FSH/age 
link (r=0.42; p<0.05) which was not found in group A 
(r=–0.20; NS). 
In normoestrogenic women (group B) the body mass 
correlated with plasma fasting levels of: insulin (r=0.76; 
p<0.001), SHBG (r=–0.51; p<0.005), IGFBP-3 (r=0.51; 
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p<0.005) as well as testosterone (r=0.67; p<0.001). 
These correlations were either insignificant or hardly 
present in group A [r=0.44;NS; r=–0.15; NS; r=–0.05; 
NS; r=–0.05; NS resp.). The above mentioned relations 
were in group B mimicked by BMI relations with insu-
lin (r=0.73; p<0.001), IGFBP-3 (r=0.49; p<0.01) and 
testosterone (r=0.68; p<0.001) levels. The correlations 
were also either insignificant or hardly present in group 
A [r=0.51;NS; r=–0.09; NS; r=–0.07; NS, resp.). The 
increase in serum insulin level followed the increase 
in BMI in both groups (rA=0.52; p<0.05; rB=0.73; 
p<0.001). 
A relation between IGF-I and its main binding 
protein (IGFBP-3) was found in both groups (i.e. 
despite the estradiol level) (rA=0.84; p<0.001; rB=0.55; 
p<0.002) (Figure 2). IGF-I level was associated with 
plasma estradiol level only in hypoestrogenic women 
(group A) (r=0.54; p<0.05; vs rB=0.03; NS) (Figure 3). 
In the normestrogenic control group hGH was 
related to SHBG (r=0.38; p<0.05) but in hypoestro-
genic group this relation was an indirect one (r=–0.64; 
p<0.02). Moreover in the controls (group B) there was 
also a correlation between plasma hGH and testoster-
one levels (r=–0.56; p<0.002) which was not only indi-
rect in group A but also became insignificant (r=0.25; 
NS). The hGH/estradiol relation was not statistically 
significant in both groups, however the in group A it 
was indirect (r= –0.44; NS) and in group B it was direct 
(r=0,301; NS).
In both groups there was an indirect relation between 
SHBG and insulin levels (rA=–0.57; p<0.05; rB=–0.47; 
p<0.01). SHBG was in group B also indirectly related 
to IGFBP-3 (r=–0.47; p<0.01), testosterone (r=–0.48; 
p<0.02) and to DHEAS (r=–0.58; p<0.001). 
Basic fasting insulin level in group B was in turn 
related to IGFBP-3 (r=0.48; p<0.01), to testosterone 
(r=0.4; p<0.05) and to DHEAS (r=0.58; p<0.001) 
whereas in group A indirectly to FSH (r=–0.57; p<0.05). 
In group A DHEAS was related to sex steroids estradiol 
(r=0.52; p<0.02) and testosterone (r=0.59; p<0.02). 
The correlation coefficients in both group are given in 
Table 3 and Table 4.
Tab. 1. Clinical characteristics of hypoestrogenic women (group A) 
and normoestrogenic controls (group B). 
Group
Parameter
A 
(n=15)
B
(n=30) p-value
Age (years) 30.2 ± 9.4 31.1 ± 8.6 NS
Body mass (kg) 66.1 ± 21.1 71.6 ± 23.5 NS
BMI 24.9 ± 7.8 26.5 ± 8.2 NS
BMI<20 20 % 16.7 % NS
20<BMI<25 40 % 50 % NS
BMI>25 40 % 33.3 % NS
LH (IU/l) 2.9 ± 5.1 10.4 ± 8.4 <0.005
FSH (IU/l) 2.7 ± 2.3 6.2 ± 1.9 <0.001
PRL (μg/l) 6.1 ± 4.6 15.3 ± 7.0 <0.001
Estradiol (ng/l) 23.5 ± 15.2 118.9 ± 68.7 <0.001
Tab. 2. Somatotropic axis and other hormonal parameters in 
hypoestrogenic women (group A) and normoestrogenic controls 
(group B).
Group
Parameter
A 
(n=15)
B
(n=30) p-value
IGF-I (μg/l) 234.9 ± 156.2 323.6 ± 127.3 <0.05
hGH (IU/l) 4.5 ± 4.9 6.4 ± 8.8 NS
IGFBP-3 (μg/l) 3.9 ± 1.3 4.3 ± 2.7 NS
SHBG (μg/l) 49.0  32.5 57.0 ± 39.6 NS
Insulin (IU/l) 24.8 ± 20.7 26.2 ± 24.1 NS
DHEAS (μg/l) 192.9 ± 126.7 218.3  88.9 NS
testosterone (μg/l) 0.42  0.26 0.56 ± 0.18 <0.05
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Fig. 1. The relation between IGF-I plasma concentration and 
age of patients with low estradiol group (group A) and in 
normoestrogenic group B.
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The stepwise multiple regression revealed DHEAS 
(β=0.96; p<0.02) and LH (β=0.30; p<0.02) as signifi-
cant predictors of the circulating IGF-I level in group 
A, while in group B none of the evaluated parameters 
significantly predicted IGF-I level. 
The same analysis was performed to determine cor-
relations between hGH and other factors. The results 
showed that in group A hGH level was significantly 
predicted by estradiol (β=–0.75; p<0.05) and SHBG 
(β=–0.68; p<0.05). In group B none of assessed factors 
significantly predicted hGH circulating levels.
DISCUSSION
Our results suggest the presence of direct, statistically 
significant IGF-I/estradiol relation in women with 
low plasma estradiol level. Not only was the relation 
observed solely in hypoestrogenic women but also 
Tab. 3. Correlation between clinical parameters, plasma levels of sex-steroids, gonadotropins, and the measured parameters of IGF-system 
in hypoestrogenic women (group A) (univariate analysis, R-values).
Age 
(yrs)
Body 
mass (kg) BMI IGF hGH Insul Prol LH FSH SHBG E2 BP3 TST DHEAS
Age (yrs) 1.000 0.599* 0.606* –0.575* 0.156 –0.060 0.150 –0.409 –0.195 –0.536 –0.477 –0.450 –0.251 –0.737*
Body mass (kg) 0.599* 1.000 0.991* –0.012 0.288 0.447 0.364 0.199 0.265 –0.153 0.009 –0.059 –0.051 0.297
BMI 0.606* 0.991 1.000 –0.027 0.250 0.517* 0.336 0.214 0.279 –0.170 0.044 –0.087 –0.073 0.232
IGF –0.575* –0.012 –0.027 1.000 –0.096 0.266 0.267 0.398 0.365 0.227 0.541* 0.840* 0.507 0.955*
hGH 0.156 0.288 0.250 –0.096 1.000 0.186 0.349 –0.013 –0.091 –0.641 –0.440 –0.448 0.250 –0.414
Insul –0.060 0.447 0.517* 0.266 0.186 1.000 0.282 0.505 0.628* –0.569 0.447 0.193 –0.113 0.222
Prol 0.150 0.364 0.336 0.267 0.349 0.282 1.000 0.049 –0.056 –0.370 0.064 0.631* 0.384 0.791*
LH –0.409 0.199 0.214 0.398 –0.013 0.505 0.049 1.000 0.735 –0.665 0.413 –0.076 –0.285 0.120
FSH –0.195 0.265 0.279 0.365 –0.091 0.628* –0.056 0.735* 1.000 –0.626 0.295 0.147 –0.454 0.013
SHBG –0.536* –0.153 –0.170 0.227 –0.641* –0.569* –0.370 –0.665* –0.626* 1.000 0.732* 0.029 –0.192 0.429
E2 –0.477 0.009 0.044 0.541* –0.440 0.447 0.064 0.413 0.295 0.732 1.000 0.130 0.239 0.525*
BP3 –0.450 –0.059 –0.087 0.840* –0.448 0.193 0.631* –0.076 0.147 0.029 0.130 1.000 0.458 0.820*
TST –0.251 –0.051 –0.073 0.507 0.250 –0.113 0.384 –0.285 –0.454 –0.192 0.239 0.458 1.000 0.587*
DHEAS –0.737* 0.297 0.232 0.955* –0.414 0.222 0.791* 0.120 0.013 0.429 0.525* 0.820* 0.587* 1.000
*p<0.05
Tab. 4. Correlation between clinical parameters, plasma levels of sex-steroids, gonadotropins, and the measured parameters of IGF-system 
in normoestrogenic women (group B) (univariate analysis, R-values).
  Age (yrs)
Body 
mass (kg) BMI IGF hGH Insul Prol LH FSH SHBG E2 BP3 TST DHEAS
Age (yrs) 1.000
Body mass (kg) 0.126 1.000
BMI 0.215 0.982* 1.000
IGF –0.533* 0.252 0.201 1.000
hGH 0.037 –0.169 –0.216 –0.096 1.000
Insul –0.008 0.764* 0.731* 0.044 –0.289 1.000
Prol 0.151 –0.042 –0.081 –0.273 0.095 0.066 1.000
LH –0.098 –0.272 –0.336 –0.085 –0.068 –0.310 0.345 1.000
FSH 0.420* –0.253 –0.214 –0.266 0.218 –0.360 0.231 0.379* 1.000
SHBG –0.049 –0.513* –0.419* –0.173 0.382* –0.467* 0.231 –0.144 0.005 1.000
E2 –0.065 –0.144 –0.178 0.029 0.301 –0.099 0.245 0.028 –0.102 0.053 1.000
BP3 –0.150 0.514* 0.488* 0.551* 0.084 0.481* –0.390* –0.302 –0.041 –0.469* –0.131 1.000
TST 0.085 0.672* 0.680* 0.220 –0.561* 0.397* –0.272 0.103 –0.033 –0.484* –0.311 0.197 1.000
DHEAS –0.377* 0.274 0.261 0.277 –0.325 0.576* 0.080 0.166 0.086 –0.582* –0.265 0.337 0.534* 1
*p<0.05
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plasma IGF-I and hGH levels were lower in this group 
despite the similar mean age and BMI of both normo- 
and hypoestrogenic women. Moreover multiple step-
wise regression analysis revealed, that in women with 
plasma estradiol level below 50 μg/l, the hGH plasma 
level could have been significantly predicted by serum 
estradiol level and sex hormone binding globulin. Our 
findings are in accordance with results of Blake et al. 
(1997) who suggest that ovarian hormonal function 
is a factor contributing even more to the plasma level 
of IGF-I than chronological ageing (Blake et al. 1997). 
Massa et al. (1993) observed a direct correlation between 
the levels of estradiol and IGF-I (r=0.69; p<0.01) in 
spontaneously menstruating women and this coeffi-
cient was similar to that obtained in our study (r=0.54; 
p<0.05) (Massa et al. 1993). Helle et al. (1998) observed 
small but significant difference in plasma levels of IGF-I 
(p<0.01) measured by RIA between the three phases of 
the menstrual cycle The highest plasma levels of IGF-I 
were seen during the follicular phase. They also found a 
correlation between plasma levels of IGF-I and estradiol 
but not progesterone at different times during the men-
strual cycle (Helle et al. 1998). Hesse et al. (1998) also 
found a direct IGF-I/estradiol correlation in pubertal 
girls (Hesse et al. 1994). The same investigators sug-
gested a direct stimulatory effect of DHEAS on IGF-I 
production as well as indirect augmentation of IGF-I 
synthesis by DHEAS stimulation of sex steroids pro-
duction. Brick et al. attributed 49% of hGH and IGF-I 
variability to free testosterone and 7% to estradiol in a 
study done on 32 women whose BMI varied from ano-
rectic to obese (Brick et al. 2010). Lapauw et al. (2009) 
observed a decrease in IGF-I concentration in men 
whose estradiol and testosterone levels were reduced by 
arometase inhibiton. On the contrary postmenopausal 
women over 55 years of age lacked both the IGF-I/
estradiol as well as IGF-I/age relationships (Wuster et 
al. 1993). However the plasma estradiol level in such 
postmenopausal women without hormone replacement 
therapy is even lower than found in pubertal girls. In 
our earlier report we observed no correlation between 
IGF-I and estradiol in severely hypoestrogenic women 
with plasma estradiol level below 25 μg/l (Milewicz et 
al. 2005). The levels of growth hormone and of course 
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Fig. 2. The relation between IGF-I and IGFBP-3 plasma 
concentrations in patients with low estradiol serum level (group 
A) and with normal estradiol level (group B).
Fig. 3. The relation between IGF-I and estradiol plasma 
concentrations in low serum estradiol patients (group A) and 
normal estradiol level patients (group B).
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estradiol vary across menstrual cycle (Faria et al. 1992). 
The presence of previously mentioned correlation 
between IGF-I/estradiol can explain IGF-I fluctuations 
during menstrual cycle (Helle et al. 1998; Van Dessel et 
al. 1996). Transdermal estradiol induction of increases 
in total and free IGF-I during hormone replacement 
therapy in perimenopausal women was reported by 
other investigators (Milewicz et al. 1999; Slowinska et al. 
1992). Lebenthal et al. (2006) measured plasma IGF-I 
in 34 short peripubertal children (17 boys and 17 girls) 
aged 8–12.5 yr before and after sex hormone prim-
ing for GH stimulation testing. In girls, priming with 
estrogen led to a supraphysiological increase in estra-
diol levels (1313.8±438.0 pmol/l) but had no effect on 
IGF-I (Lebenthal et al. 2006). Such a high estradiol level 
could have destroyed the link between estradiol and 
IGF-I or lasted too short and did not induce the IGF-I 
increase. The effect of estradiol supplementation on 
somatotropic axis depends on route of administration 
and dose (Blake et al. 1997; Sonnet et al. 2007; Stefano 
et al. 2003). Oral estrogens increase basal and GH-RH 
stimulated GH secretion, but depress IGF-I, whereas 
transdermal estradiol administration is either irrelevant 
in this regard or even increases the IGF-I level (Slowin-
ska et al. 1992; Kelly et al. 1993; Weissberger et al. 1991; 
Wolinska-Witord et al. 2000). Sex steroids exert priming 
effect on both hGH and IGF-I leading to augmentation 
of the IGF-I action by 45 to 80% (Itagane et al. 1991). 
In ovariectomized animals high dose estradiol supple-
mentation caused the decline in plasma IGF-I level, 
whereas low dose one did not influence the somato-
tropic axis or increase the IGF-I level (Kalu et al. 1994). 
Kanbur-Oksüz et al. (2004) conducted a cross-sectional 
study to investigate the relationships among IGF-1 axis 
and sex steroids during pubertal development in 205 
healthy adolescents aged 9–17 years. In their study, 
estradiol levels of girls and testosterone levels of boys 
differed significantly between stages, and in both sexes, 
plasma IGF-1 levels and IGF-1/IGFBP-3 ratios were sig-
nificantly correlated with sex steroid levels. Sex steroids 
which levels increased with pubertal development, 
caused a rise in IGF-I levels and IGF-1/IGFBP-3 ratios 
(Kanbur-Oksuz et al. 2004). Rosenfeld et al. (1998) sug-
gests a biphasic effect of estradiol influence on growth, 
stimulatory in low doses, but inhibitory in high ones. 
Helle et al. (2002) studied the relation of IGF-I to sex 
steroids in 39 premenopausal and 114 postmenopausal 
women. These investigators found no correlation 
between estradiol and IGF-I in both pre- and post-
menopausal women but they observed a link between 
estradiol and IGF-II in low estradiol postmenopausal 
group. However they were unable to show a statistically 
significant age/IGF-I correlation in any group, neither 
did they find any link between body mass and IGFBP-
3, BMI, or IGFBP-3 in either of groups, whereas we 
were able to show an association in normoestrogenic 
controls. Helle et al. (2002) showed the IGF-I/IGFBP-3 
link which was also showed in our study. They also 
observed an indirect link link between IGFBP-3 and 
SHBG in the hypoestrogenic women. In our study there 
was no relationship in between IGFBP-3 and SHBG in 
the hypoestrogenic group but a significant indirect link 
in normoestrogenic controls could be seen. The reason 
for the discrepancies between our results and the data 
of Helle et al. (2002) can be explained by the differences 
in the age of examined women: our patients were at 
least 20 years younger. Furthermore, our hypoestro-
genic group had also higher plasma testosterone level 
than the normoestrogenic controls. Helle et al. (2002) 
did not report the mean testosterone level in for either 
of their study groups.
Sex hormone binding globulin (SHBG) is of hepatic 
origin. Its synthesis is enhanced by estradiol and thy-
roid hormones and reduced by insulin and IGF-I (Nes-
tler et al. 1991; Singh et al. 1990). As a result of body 
mass increase, SHBG level declines and the ratio of free 
estradiol to testosterone becomes higher. The dimin-
ished SHBG level is an independent risk factor for 
noninsulin-dependent diabetes mellitus (Haffner et al. 
1993). In our study we observed an increase in body 
mass with ageing in hypoestrogenic women and a cor-
related decrease in SHBG level. In the same group of 
patients with low estradiol (group A) the mean SHBG 
plasma level tended to be lower. In our earlier studies 
we also observed the BMI/age relation in women with 
low estradiol level as well as the correlation between 
leptin and age and leptin and DHEAS (Krzysiek et al. 
1998; Milewicz et al. 1999). Furthermore, our present 
results indicate the insulin induced decline of SHBG 
in groups examined (rA=–0.57; p<0.05; rB=–0.47; 
p<0.01). Taking into account the direct link between 
IGF-I and IGFBP-3 observed also in our study, the 
indirect relation between IGFBP-3 and SHBG that we 
observed indicates the involvement of IGF-I in regula-
tion of hepatic SHBG synthesis. 
The plasma levels of insulin and IGFBP-1 are corre-
lated indirectly whereas direct correlations were found 
for insulin and IGF-I and for insulin and IGFBP-3 con-
centrations (Conover et al. 1992). A similar correlation 
(insulin/IGFBP-3) was observed in our study. Group 
A consisted of women with hypothalamo-hypophyseal 
insufficiency and that resulted in low gonadotropin, 
estradiol and testosterone levels. Insulin and IGF-I 
potentate the LH action on ovarian theca cell androgen 
production (Bergh et al. 1993). In polycystic ovary syn-
drome patients, the high IGF-I plasma level correlated 
with both plasma insulin and androgenism (Milewicz 
et al. 1998), which can explain the insulin/testosterone 
correlation observed in our study as well as LH influ-
ence on IGF-I level.
Concluding, low circulating levels of hGH, IGF-I can 
be observed in women with plasma estradiol level below 
50 μg/l. In women with both low estradiol level and low 
hGH/IGF-I axis activity, a link between plasma con-
centrations of estradiol and IGF-I was found, whereas 
in normoestrogenic women of similar age, with high 
863Neuroendocrinology Letters Vol. 32 No. 6 2011 • Article available online: http://node.nel.edu
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somatotropic activity such link could not be observed. 
Therefore estradiol influence on hGH/IGF-I axis seems 
biphasic.
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